Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Inventory (2016 - 2025)

Adma Biologics (ADMA) has disclosed Change in Inventory for 13 consecutive years, with $9.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 725.67% year-over-year to $9.8 million, compared with a TTM value of $36.2 million through Dec 2025, up 1456.42%, and an annual FY2025 reading of $36.2 million, up 1456.42% over the prior year.
  • Change in Inventory was $9.8 million for Q4 2025 at Adma Biologics, up from $5.2 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $19.3 million in Q2 2025 and bottomed at -$8.0 million in Q3 2024.
  • Average Change in Inventory over 5 years is $6.2 million, with a median of $5.4 million recorded in 2021.
  • The sharpest move saw Change in Inventory skyrocketed 2571.53% in 2023, then plummeted 699.48% in 2024.
  • Year by year, Change in Inventory stood at $10.6 million in 2021, then tumbled by 96.54% to $366457.0 in 2022, then surged by 2571.53% to $9.8 million in 2023, then crashed by 116.0% to -$1.6 million in 2024, then skyrocketed by 725.67% to $9.8 million in 2025.
  • Business Quant data shows Change in Inventory for ADMA at $9.8 million in Q4 2025, $5.2 million in Q3 2025, and $19.3 million in Q2 2025.